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Clinical Infectious Diseases
M A J O R A R T I C L E
The Burden of Hepatitis C Infection–Related Liver Fibrosis
in the United States
R. Monina Klevens,1 Lauren Canary,1 Xiaohua Huang,2 Maxine M. Denniston,1 Anthony E. Yeo,2 Rick L. Pesano,2 John W. Ward,1 and Scott Holmberg1
1Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia; and 2Quest Diagnostics, Madison, New Jersey
Background. Knowledge of the estimated proportion of hepatitis C virus (HCV)-infected persons with advanced fibrosis or
cirrhosis is critical to estimating healthcare needs.
Methods. We analyzed HCV-related testing conducted by Quest Diagnostics from January 2010 through December 2013. Tests
included hepatitis C antibody, HCV RNA, HCV genotype (nucleic acid tests [NAT]), liver function tests, and platelet counts; patient
age was also determined. Aspartate aminotransferase (AST)-to-platelet ratio (APRI) was calculated as = 100*(aspartate aminotrans-
ferase [AST]/upper limit of AST)/platelet. Fibrosis-4 (FIB-4) was calculated as (age × AST)/(platelet ×√ alanine aminotransferase
[ALT]). Persons were “currently infected” if they had ≥1 positive HCV NAT; “in care” if a positive RNA test was followed <6 months
by ≥1 additional NAT(s), or ALT, AST, and platelets <90 days, or any test ordered by an infectious diseases or gastroenterology
specialist; and “evaluated for treatment” if they had a genotype test.
Results. Approximately 10 million HCV test results were analyzed, representing 5.6 million unique patients. Of the 2.6 million
patients with data to estimate liver disease, 5% were currently infected. Among those currently infected, APRI and FIB-4 scores
indicated that 23% overall—and 27% among the cohort born during 1945–1965—had advanced fibrosis or cirrhosis at first diagnosis.
A total of 54% of infected were in care and 51% of infected with advanced fibrosis or cirrhosis were evaluated for treatment.
Conclusions. Testing from a large US commercial laboratory indicates that about 1 in 4 HCV-infected persons have levels of liver
disease put them at highest risk for complications and could benefit from immediate antiviral therapy.
Keywords. hepatitis C virus; epidemiology; fibrosis.
Deaths as recorded on death certificates associated with hepati-
tis C virus (HCV) infection have steadily increased in the Unit-
ed States, exceeding deaths recorded on death certificates for
human immunodeficiency virus since 2007 [1], even though
death certificates record less than one-fifth of all persons
dying with HCV [2]. Persons dying with HCV infection are
25 years younger than those dying without HCV infection
[3]. The appearance of clinical complications of HCV might
be the first indication of infection, as infection may be asymp-
tomatic for decades. The early identification of asymptomatic
HCV-infected persons with subsequent linkage to care and
treatment, if appropriate, is estimated to prevent more than
320 000 deaths associated with HCV-related complications be-
tween 2010 and 2060 [4]. To prevent further complications and
deaths, the Centers for Disease Control and Prevention (CDC)
[5] and the US Preventive Services Task Force (USPSTF) [6] rec-
ommend a 1-time screening of persons born during 1945–1965
to identify and diagnose infected persons who might be unaware
of their infection.
Once diagnosed, HCV-infected persons can benefit from
novel, highly effective anti-HCV therapies. Current clinical
guidelines recommend treatment for all patients with chronic
HCV infection, unless individuals will not benefit from treat-
ment [7].Controlling for other factors, advanced fibrosis (Meta-
vir stage F3) and compensated cirrhosis (Metavir stage F4) are
strong predictors of progression to hepatocellular carcinoma or
decompensation [8]. Biopsy had long been the gold standard to
stage liver fibrosis of any etiology, but its costs and other limi-
tations have led clinicians to use a combination of noninvasive
methods to assess liver fibrosis [7, 9]. Fibrosis-4 (FIB-4) score is
frequently used because of its demonstrated statistical associa-
tion with HCV-related liver disease staging, especially in iden-
tifying advanced fibrosis or cirrhosis [10, 11].
In this study, we used laboratory data from a large commer-
cial laboratory service in the United States to describe the bur-
den of fibrosis among persons with chronic HCV infection,
evaluate stage of fibrosis at first HCV diagnosis, and use labora-
tory measures to describe persons in care and those evaluated
for HCV treatment.
METHODS
Quest Diagnostics provides laboratory testing services to ap-
proximately half of the physicians and hospitals in the United
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States. Approximately 150 million test requisitions are pro-
cessed annually. Test results are routinely reported back through
providers for clinical care. CDC asked 6 collaborating health
departments to track the laboratory source of newly reported
hepatitis C cases during 2012–2014. Quest was the source of
11%–73% of new cases.
Quest stores selected information for each test in secure da-
tabases. After finalizing a data-sharing agreement with CDC in
2013, Quest provided CDC with longitudinal, de-identified data
from HCV-related tests ordered by physicians in the United
States between January 2010 and December 2013. The tests
analyzed were HCV antibody (Ab), HCV-RNA, genotype
(LiPA), alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), and platelet count from a complete blood count.
Nucleic acid tests (NATs) included any RNA or genotype test.
Hepatitis C Ab measurements were performed by immunoassay
(Ortho-Clinical Diagnostics, Inc., Rochester New York). HCV
viral RNA quantitative measurements were performed by poly-
merase chain reaction (PCR), using the COBAS Ampliprep/
COBAS TaqMan HCV test kit (Roche Molecular Systems,
Inc., Branchburg, New Jersey). HCV viral RNA qualitative,
transcription-mediated amplification test was performed using
the Versant HCV RNA qualitative assay (Gen-Probe Inc.,
San Diego, California). HCV Ab, recombinant immunoblot
assay (RIBA) test (Chiron RIBA HCV 3.0 SIA) was used to con-
firm the presence of HCV antibodies (Ortho Clinical Diagnos-
tics, Raritan, New Jersey) through 2012. As of May 2013, an
option of Ab testing with reflex to RNA PCR became available.
A unique patient identification (ID) was created to extract pa-
tient data from the Quest clinical results database. SAS statistical
software (version 9.3; Cary, North Carolina) was used to clean
and prepare data prior to delivery to CDC via a password-pro-
tected secure ftp (file transfer protocol) site (Secure Access
Management Service), hosted by CDC.
Data Analyses
The patient ID was used to structure the data such that interpre-
tation could be made at the patient level. Patient year of birth
was used to categorize persons into 1 of 3 cohorts: born before
1945, born from 1945–1965, and born after 1965. In addition to
year of birth, records contained limited patient and provider
characteristics including payer type, specialty of the provider or-
dering the test, and the first 3 digits of the patient residence zip
code, which were used to define state of residence. Regions were
categorized using 9 standard US Department of Health and
Human Services groups as follows: New England (Connecticut,
Maine, Massachusetts, New Hampshire, Rhode Island, and Ver-
mont); Mid-Atlantic (New Jersey, New York State, and Pennsyl-
vania); East North Central (Illinois, Indiana, Michigan, Ohio,
and Wisconsin); West North Central (Iowa, Kansas, Minnesota,
Missouri, Nebraska, North Dakota, and South Dakota); South
Atlantic (Delaware, District of Columbia, Florida, Georgia,
Maryland, North Carolina, South Carolina, Virginia, and
West Virginia); East South (ES) Central (Alabama, Kentucky,
Mississippi, and Tennessee); West South (WS) Central (Arkan-
sas, Louisiana, Oklahoma, and Texas); Mountain (Arizona,
Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and
Wyoming); and Pacific (Alaska, California, Hawaii, Oregon,
and Washington).
We defined a person as “‘currently infected”’ if they had 1 or
more HCV NAT tests with a positive result (eg, detectable RNA
or valid genotype result; see flow diagram). A person was con-
sidered “never infected” if they only had documentation of a
negative HCV Ab test and were considered “resolved/cured” if
they had a positive Ab result and a negative RNA result. We ex-
cluded from this analysis anyone with only a negative RNA test
or only a positive Ab test. We defined “in care” as any person
with a positive RNA test who within 6 months also had any of
the following: ≥1 additional NATs; or ALT, AST, and platelets
ordered within 90 days (routine components of a hepatic func-
tion panel, comprehensive metabolic panel, and complete blood
count); or any test ordered by an infectious diseases or gastro-
enterology specialist. We defined a person as “evaluated for
treatment” if they had a genotype test, since guidelines recom-
mend an HCV genotype test before initiating antiviral medica-
tion [7].
We used existing noninvasive serum fibrosis markers to cate-
gorize persons by stage of liver disease [11].AST-to-platelet ratio
(APRI) was calculated as = 100*(AST/upper limit of AST)/plate-
let. Advanced fibrosis or cirrhosis was defined as APRI > 1.5. The
FIB-4 score was calculated using the formula: (age × AST)/
(platelet ×√ (ALT)), when all 3 test results and age were avail-
able. We only used tests that were within ±90 days of the first
HCV test result for a given patient (ie, first NAT test for “current-
ly infected,” first RNA negative test for resolved/cured, first Ab
negative test for never infected) to calculate APRI and FIB-4.
Among persons with multiple liver function test results available
within the 90-day window, we selected the one closest to the
given HCV test result. After the initial description of the popu-
lation using APRI, which produced similar disease staging clas-
sification for the population, we used FIB-4 in further analyses
because it accounted for age as a factor. Advanced fibrosis or cir-
rhosis was defined as FIB-4 score >3.25; “moderate” fibrosis was
FIB-4 of 1.45–3.25; and no or minimal fibrosis was <1.45 [10].
We calculated proportions of persons by infection status,
stage of liver fibrosis, and cohort year of birth. We observed
the proportion of persons with advanced fibrosis or cirrhosis
over the 4-year period and used logistic regression models to
evaluate factors associated with our proxy measures for the fol-
lowing 2 outcomes among persons who were NAT positive:
being in care and being evaluated for treatment. All factors in-
vestigated were included in the initial multivariable model for
each outcome (birth cohort, sex, payer, provider specialty, and
region for both outcomes plus severity of fibrosis for being in
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care) since all were found to be significant in univariate logistic
models. Multivariable models were built using backward elim-
ination; final models included variables that had a statistically
significant association with the outcome plus birth cohort and
sex, which were retained as possible confounders even if not sig-
nificant. We conducted χ2 testing of comparisons; however, be-
cause of the large number of observations, almost all results
were statistically significant. Statements in results reflect an as-
sessment of the magnitude of the effect. Trends in stage at diag-
nosis were tested using the Cochran-Armitage trend test. P < .05
was considered statistically significant and was used for retain-
ing variables during multivariate model building.
RESULTS
Quest Diagnostics performed 9 785 976 HCV tests in the Unit-
ed States during the 4-year period. These tests represent
9 493 037 patient encounters and 5 651 742 unique persons
(Figure 1). We classified 292 681 persons as currently infected,
59 965 as cured/resolved, and 5 017 307 persons as never infect-
ed. We excluded from analysis 135 663 persons with a positive
Ab test only, 146 034 persons with an undetectable RNA result
only, and 92 persons with HCV test name missing. Fifty-one
percent of currently infected, 61% of cured/resolved, and 48%
of never infected persons had age recorded and ALT, AST,
and platelet results within 90 days of their first HCV test, allow-
ing calculation of FIB-4. There were no differences in gender or
age among infected persons with and without a calculable FIB-4
(data available upon request).
Burden of Liver Fibrosis
APRI results were consistent with FIB-4 results. Overall, 22% of
persons with current infection, 11% of persons with resolved/
cured infection, and 3% of persons never infected had advanced
fibrosis or cirrhosis (APRI >1.5). As expected, the frequency of
advanced fibrosis or cirrhosis based on FIB-4 (Table 1) was
higher among infected than resolved/cured or never infected
persons. And, among persons with current infection, those
born before 1945 had the highest frequency of advanced fibrosis
or cirrhosis.
The currently infected population overall was more frequent-
ly male, aged 40–59 years, and had tests paid for by private in-
surance (Table 2). With increasing level of fibrosis, the
proportion of persons aged ≥60 years, the proportion with
Medicare as the payer of their tests, and the proportion whose
tests were ordered by gastroenterology specialists increased
(Table 2).
Stage at First Diagnosis
Among persons newly diagnosed with HCV, the percentage
with advanced fibrosis or cirrhosis was constant over the
4-year period (12% in 2010, 12% in 2011, 13% in 2012, and
12% in 2013; P < .0001). Similarly, among persons born during
1945–1965, the percentage with advanced fibrosis or cirrhosis
was higher but constant in the 4-year period (27% in 2010,
26% in 2011, 28% in 2012, and 28% in 2013; P < .0001).
Currently Infected in Care
There were 158 363 persons, or 54% of all of those currently in-
fected, who met our criteria for being in care; thus, 134 318, or
46%, were considered not to be in care. Specifically, within
6 months of the first positive RNA test, 18% had a follow-up
NAT, 18% had the hepatic panel tests, and 8% had a test ordered
by an infectious diseases or gastroenterology specialist. Com-
pared with persons not in care, the following factors were more
frequent among persons in care: birth year in 1945–1965 (70% vs
Figure 1. Definition of Hepatitis C Virus (HCV) Disease Status for Analysis, 2010–2013. Abbreviations: Ab, antibody; FIB-4, fibrosis-4; NAT, nucleic acid test.
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65%), female (38% vs 34%), having private insurance (68% vs
50%), tested by a gastroenterologist (35% vs 2%), having ad-
vanced fibrosis or cirrhosis (21% vs 6%), and residence in the
Mid- or South Atlantic regions (44% vs 36%). All factors were
statistically significant in univariate analyses, and most were sig-
nificant in the adjusted analysis. However, in univariate analyses,
payer types of Medicaid, Medicare, and private insurance were
the only factors with a crude prevalence ratio >2 for being in
care. Severity of liver fibrosis was not strongly associated with
being in care in either univariate or adjusted analysis (all odds
ratios were 1.0–1.1).
Evaluated for Treatment
Among the 33 891 persons with detectable RNA and advanced
fibrosis or cirrhosis, 50.6% had 1 or more genotype tests during
the 4-year period, which was our indicator for evaluated for an-
tiviral treatment. While the prevalence ratios from logistic re-
gression analysis were frequently statistically significant, none
of the factors we investigated had a prevalence ratio ≥2 for hav-
ing a genotype test (Table 3). In univariate analyses, being born
from 1945–1965 and being born after 1965 had some of the
highest prevalence ratios for having a genotype test. Similarly,
Medicaid as a payer; having tests ordered by a gastroenterology,
infectious diseases specialist, or a physician assistant; and resi-
dence in select regions of the United States (ES Central, Pacific,
South and Mid-Atlantic, and WS Central) had some of the
highest prevalence ratios for being evaluated for treatment. In
the adjusted model, the highest prevalence ratios were in
selected regions of the United States (ES Central, Pacific, Mid
and South Atlantic, and WS Central) and for persons tested
by a gastroenterologist or infectious disease specialist, but
none were ≥2.
DISCUSSION
We used commercial laboratory testing data to measure the bur-
den of advanced fibrosis and cirrhosis in the US population. Re-
sults suggest that among the currently infected, 23% overall and
27% of those born from 1945–1965 had advanced fibrosis or
cirrhosis. In contrast, only 3% of tested but uninfected persons
had advanced fibrosis or cirrhosis. Persons with advanced
fibrosis and cirrhosis are at highest risk of HCV-related compli-
cations and urgently require linkage to care. Laboratory testing
data suggest that about half of infected persons with advanced
fibrosis or cirrhosis were not evaluated for treatment. Given ad-
vances in treatment options [12], we expect the proportion of
infected persons who are treated to increase over time. Addi-
tionally, many of the infected persons not in care were tested
for HCV infection by a primary care physician. These findings
indicate a need for training of primary care physicians in HCV
screening, management, and referral of patients with advanced
liver disease to specialists.
At the population level, measurements of advanced HCV-
related liver disease are important to evaluate the impact of
HCV screening recommendations and to support healthcare re-
sources planning for persons infected. Applying the overall 23%
Table 1. Burden of Liver Fibrosis Among All Persons Tested for Hepatitis C, by Infection Status and Birth Cohort, 2010–2013
Fibrosis Severitya Currently Infectedb Resolved/Curedc Never Infectedd
Alle n = 150 475 (%) n = 36 319 (%) n = 2 413 191 (%)
None/mild 59 933 39.8 26 669 73.4 1 950 621 80.8
Moderate 55 524 36.9 7818 21.5 388 218 16.1
Advanced /cirrhosis 35 018 23.3 1832 5.0 74 352 3.1
Persons born before 1945e
None/mild 776 7.4 870 28.5 69 910 30.2
Moderate 4787 45.9 1710 56.0 129 066 55.7
Advanced/cirrhosis 4876 46.7 476 15.6 32 844 14.2
Persons born from 1945–1965e
None/mild 30 474 29.3 13 017 66.1 619 693 71.3
Moderate 45 268 43.5 5477 27.8 215 470 24.8
Advanced/cirrhosis 28 271 27.2 1209 6.1 33 387 3.8
Persons born after 1965e
None/mild 28 683 79.6 12 782 94.3 1 261 018 96.1
Moderate 5469 15.2 631 4.7 43 682 3.3
Advanced/cirrhosis 1871 5.2 147 1.1 8121 0.6
Abbreviation: FIB-4, fibrosis-4.
a Severity was defined based on FIB-4 scores: none/mild, < 1.45; moderate, 1.45–3.25; advanced/cirrhosis, > 3.25. FIB-4 score was calculated using the formula (age × aspartate
aminotransferase [AST])/(platelet ×√ alanine aminotransferase [ALT]). Fibrosis level based on availability of ALT/AST/platelet results within ±90-day window of first test of a given type for
each category (ie, first RNA+/genotype test, first positive antibody and RNA negative test, or first negative antibody test, respectively).
b Currently infected included persons with either a positive hepatitis C virus (HCV)-RNA or a genotype result.
c Resolved/cured included persons with a positive HCV antibody result and a negative RNA result.
d Never infected included persons with a negative HCV antibody result.
e All χ2 tests for comparisons were P < .0001.
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with advanced liver disease to the estimated 3.5 million infected
persons in the population [13] suggests there may be more than
800 000 persons in the United States with urgent need of med-
ical management [14]. Clearly, multiple barriers to treatment
exist in the United States. Cost and restricted access to care
may be the greatest barriers to treatment [15], despite evidence
that treating infected persons early is cost effective [16]. An in-
sufficient number of trained providers may be another barrier
to managing this population’s healthcare [17]. Infectious diseas-
es specialists might improve identification of asymptomatic per-
sons by integrating HCV screening, evaluation, and treatment
with other medical services, as recommended in the American
Association for the Study of Liver Disease and the Infectious
Disease Society of American guidelines [7].
Our finding of the frequency of advanced liver disease falls
within the values from studies of different populations. Backus
Table 2. Characteristics of Persons Currently Infected With Hepatitis C Virus, by Stage of Liver Fibrosis, 2010–2013a
Characteristic
Fibrosis Severity
All Fibrosis Levels
None/Mild Moderate Advanced/Cirrhosis
(FIB-4 < 1.45) (FIB-4 1.45–3.25) (FIB-4 > 3.25)
Number % Number % Number % Number %
Total 59 933 55 524 35 018 150 475
Gender
Female 23 751 39.6 19 537 35.2 12 710 36.3 55 998 37.2
Male 36 081 60.2 35 876 64.6 22 230 63.5 94 187 62.6
Missing/unknown 101 0.2 111 0.2 78 0.2 290 0.2
Age group (y)
≤19 820 1.4 17 0.0 5 0.0 842 0.6
20–39 19 523 32.6 2054 3.7 536 1.5 22 113 14.7
40–59 35 131 58.6 37 108 66.8 21 593 61.7 93 832 62.4
≥60 4459 7.4 16 345 29.4 12 884 36.8 33 688 22.4
Missing/unknown 0 0.0 0 0.0 0 0.0 0 0.0
Payer
Client bill 1071 1.8 837 1.5 630 1.8 2538 1.7
Patient 508 0.8 441 0.8 281 0.8 1230 0.8
Medicare 4707 7.9 7871 14.2 6318 18.0 18 896 12.6
Medicaid 7614 12.7 5601 10.1 3785 10.8 17 000 11.3
Private insurance 45 006 75.1 39 777 71.6 23 272 66.5 108 055 71.8
Missing/unknown 1027 1.7 997 1.8 732 2.1 2756 1.8
Provider specialty
Gastroenterology 11 593 19.3 13 701 24.7 10 623 30.3 35 917 23.9
Infectious disease 1627 2.7 1638 3.0 881 2.5 4146 2.8
Physician assistant 2754 4.6 2164 3.9 1306 3.7 6224 4.1
Primary care 21 653 36.1 19 789 35.6 11 208 32.0 52 650 35.0
Registered nurse 2800 4.7 2113 3.8 1286 3.7 6199 4.1
Otherb 4913 8.2 3855 6.9 2516 7.2 11 284 7.5
Missing/unknown 14 593 24.3 12 264 22.1 7198 20.6 34 055 22.6
US region
East North Central 1856 3.1 1960 3.5 1313 3.7 5129 3.4
East South Central 1307 2.2 916 1.6 560 1.6 2783 1.8
Mid-Atlantic 13 179 22.0 13 800 24.9 8061 23.0 35 040 23.3
Mountain 1398 2.3 1411 2.5 1004 2.9 3813 2.5
New England 3573 6.0 2497 4.5 1370 3.9 7440 4.9
Pacific 21 258 35.5 16 031 28.9 9754 27.9 47 043 31.3
South Atlantic 10 160 17.0 11 175 20.1 7149 20.4 28 484 18.9
West North Central 1205 2.0 1065 1.9 585 1.7 2855 1.9
West South Central 4877 8.1 5596 10.1 4382 12.5 14 855 9.9
Missing/unknown 1120 1.9 1073 1.9 840 2.4 3033 2.0
All χ2 tests for comparisons were P < .0001.
Abbreviation: FIB-4, fibrosis-4.
a FIB-4 was calculated using the formula (age x AST)/(Platelet x√ (ALT)).
b Includes all other specialties with less than 5% frequency.
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and colleagues found that 13% of HCV-infected US veterans
had cirrhosis alone [18]. Kanwal analyzed claims data from a
large insurer and found that 18% of HCV-infected persons
had cirrhosis alone [19]. Udompap and colleagues analyzed
data sampled from the civilian, household population and
found that 16% had FIB-4 values >3.25 [20]. Finally, in a cohort
of more than 10 000 persons with HCV infection in care, Holm-
berg found 38% had advanced fibrosis (Metavir F3) or cirrhosis
(Metavir F4) [11].Our finding that about half of those with cur-
rent infection had been evaluated for treatment is only slightly
lower than the observed 54% of persons in care who had treat-
ment prescribed [8].
We found a large proportion of infected persons (46%) with
no laboratory evidence of follow-up after diagnosis. Further-
more, our finding that severity of HCV-related liver fibrosis
was not strongly associated with being in care is of concern.
One half of persons not in care had private insurance, and
32% were tested by a primary care provider. Currently, several
reflex tests are available, including anti-HCV with reflex to RNA
PCR and PCR with reflex to genotype; use of these tests could
Table 3. Factors Associated With Being Evaluated for Treatment Among Persons With Advanced Fibrosis or Cirrhosis and Hepatitis C Virus Infection
(n = 33 891)
Characteristic
Number and % With
RNA Positive and
Genotype n = 17 163
Number and % With
RNA Positive Without
Genotype n = 16 728 Crude PR (95% CI) Adjusted PR (95% CI)
Birth cohort
Born <1945 1955 11.4 2770 16.6 Ref Ref
Born 1945–1965 14 176 82.6 13 172 78.7 1.25 (1.21–1.30)*** 1.20 (1.16–1.24)***
Born >1965 1032 6.0 786 4.7 1.37 (1.30–1.45)*** 1.32 (1.25–1.39)***
Missing/unknown 0 0.0 0 0.0 . . . . . .
Sex
Male 11 010 64.1 10 490 62.7 1.03 (1.01–1.05)** 1.01 (0.99–1.03)
Female 6126 35.7 6190 37.0 Ref Ref
Missing/unknown 27 0.2 48 0.3 0.72 (0.53–0.98)* 0.68 (0.49–0.93)**
Payer
Client bill 276 1.6 273 1.6 1.12 (1.02–1.22)* 1.20 (1.10–1.30)***
Patient 136 0.8 125 0.8 1.16 (1.03–1.31)* 1.13 (1.00–1.27)
Medicare 2750 16.0 3365 20.1 Ref Ref
Medicaid 1980 11.5 1650 9.9 1.21 (1.16–1.26)*** 1.17 (1.12–1.21)***
Private insurance 11 730 68.4 10 928 65.3 1.15 (1.12–1.19)*** 1.09 (1.06–1.13)***
Missing/unknown 291 1.7 387 2.3 0.95 (0.87–1.05) 0.99 (0.91–1.08)
Provider specialty
Gastroenterology 5935 34.6 4330 25.9 1.31 (1.25–1.38)*** 1.32 (1.26–1.38)***
Infectious disease 480 2.8 382 2.3 1.27 (1.18–1.36)*** 1.27 (1.18–1.36)***
Physician assistant 677 3.9 586 3.5 1.22 (1.14–1.30)*** 1.20 (1.12–1.29)***
Primary care 5125 29.9 5741 34.3 1.07 (1.02–1.13)** 1.07 (1.02–1.13)**
Registered nurse 588 3.4 650 3.9 1.08 (1.00–1.16)* 1.07(0.99–1.15)
Othera 1082 6.3 1378 8.2 Ref Ref
Missing/unknown 3276 19.1 3661 21.9 1.07 (1.02–1.13)** 1.07 (1.01–1.12)*
CDC region
East North Central 499 2.9 763 4.6 1.04 (0.94–1.16) 1.00 (0.90–1.12)
East South Central 322 1.9 226 1.4 1.55 (1.39–1.73)*** 1.47 (1.33–1.64)***
Mid-Atlantic 4042 23.6 3887 23.2 1.35 (1.24–1.46)*** 1.34 (1.24–1.46)***
Mountain 360 2.1 590 3.5 Ref Ref
New England 635 3.7 705 4.2 1.25 (1.13–1.38)*** 1.18 (1.07–1.30)**
Pacific 4893 28.4 4419 26.4 1.39 (1.28–1.51)*** 1.36 (1.25–1.47)***
South Atlantic 3600 21.0 3374 20.2 1.36 (1.25–1.48)*** 1.31 (1.21–1.42)***
West North Central 232 1.4 340 2.0 1.07 (0.94–1.22) 1.03 (0.90–1.17)
West South Central 2282 13.3 1986 11.9 1.41 (1.29–1.54)*** 1.31 (1.21–1.43)***
Missing/Unknown 298 1.7 438 2.6 1.07 (0.95–1.20) 1.06 (0.94–1.20)
FIB-4 score was calculated using the formula (age × aspartate aminotransferase)/(platelet ×√ alanine aminotransferase) and advanced fibrosis or cirrhosis was FIB-4 > 3.25.
Abbreviations: CDC, Centers for Disease Control and Prevention; CI, confidence interval; PR, prevalence ratio; Ref, reference category.
a Includes all other specialties, which accounted for <5% of the total.
*P < .05 for t test of model coefficient.
**P < .01 for t test of model coefficient.
***P < .001 for t test of model coefficient.
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reduce these gaps. Successful treatment of HCV infection re-
duces the risk of complications for the individual and reduces
potential transmission to others. However, regardless of wheth-
er infected persons can be treated, they should be monitored
and counseled to prevent complications related to alcohol use
or medication toxicity.
Region and specialist were associated with being assessed for
treatment among infected persons with advanced liver disease.
Most of the infected persons in our study population had pri-
vate insurance or publicly funded care so that variability in
treatment coverage in this group warrants further investigation.
Limitations of our study include, first, that data from labora-
tory testing reflect persons tested, regardless of reason for test-
ing and therefore do not include persons who were never
screened or those for whom a patient ID could not be assigned.
Many may have had a clinical indication, but we are unable to
determine howmany. Furthermore, we included data from 1 US
laboratory, and these tests might not represent all persons tested
nationally or those with select testing performed elsewhere;
however, this source provides a large sampling of the total
number of patients tested and infected in the United States.
We used APRI and FIB-4, which are not the clinical gold stan-
dard, but are gaining acceptance as epidemiologic tools. We
developed laboratory-based definitions for events that would
be more accurately measured using direct chart review (ie, in
care, evaluated for treatment). In addition, there are limita-
tions intrinsic to every test (ie, sensitivity/specificity of the an-
tibody, PCR, error in ALT, AST and platelets, reliability).
Misclassification of cases by infection status could occur if per-
sons were tested for HCV Ab during the 4-year period but
did not have an RNA or genotype test during the same period.
Finally, we might underestimate the frequency of being in care
or assessed for treatment if persons were tested for antibodies
in a Quest laboratory but followed up with a NAT at a different
laboratory.
Early identification of the estimated 3.5 million US persons
with chronic HCV infection and the estimated 800 000 with ad-
vanced fibrosis or cirrhosis is critical for prevention of forecast-
ed premature deaths and other complications by 2030 [21]. The
findings described in this study support the CDC and USPSTF
recommendations for HCV testing and appropriate referral of
persons born from 1945–1965 as well as efforts to reduce bar-
riers to care among those who are HCV infected.
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